← Back to Search

Smoking Cessation Agent

1 for Smoking (MMTASC Trial)

Phase 2

Waitlist Available

Research Sponsored by Vancouver Coastal Health

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 9-12 weeks; 9-26

Awards & highlights

MMTASC Trial Summary

The main hypotheses guiding the study are: Stable methadone maintenance patients receiving varenicline will be more likely to maintain abstinence than patients receiving placebo There will be no differences in the type and number of symptoms reported between stable methadone maintenance patients receiving varenicline and placebo There will be no changes in methadone dosage between abstinent and non-abstinent smokers There will be no differences in efficacy, withdrawal symptoms, and safety of varenicline between male and female participants

MMTASC Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 9-12 weeks; 9-26

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~9-12 weeks; 9-26

This trial's timeline: 3 weeks for screening, Varies for treatment, and 9-12 weeks; 9-26 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

7-day point prevalence of abstinence, 9-12 week continuous abstinence, 9-26 week continuous abstinence

Secondary outcome measures

Sex differences in the efficacy, withdrawal symptoms, and safety of varenicline

Side effects data

From 2022 Phase 4 trial • 39 Patients • NCT04011280

50%

Dysgeusia

50%

Anxiety

36%

Sleep Disturbances

29%

Nausea

21%

Depression

21%

Agitation

21%

Headache

14%

Allergies

14%

Heartburn

14%

Cold

14%

Back Pain

Cellulitis

Sinusitis

Stomach Pain

Panic

Angina

Aggression

Palpitations

Rash

Confusion

Dizziness

Fatigue

Leg Spasms

Increased Blood Pressure

Malaise

Weight Gain

Gum Disease

Pharyngitis

Leg Cramps

Muscle Pain

100%

80%

60%

40%

20%

Study treatment Arm

Low Dose Varenicline

Standard Dose Varenicline

MMTASC Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: 1Experimental Treatment1 Intervention

Group II: placeboPlacebo Group1 Intervention

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Varenicline

FDA approved

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

British Columbia Centre of Excellence for Women's HealthUNKNOWN

Vancouver Coastal HealthLead Sponsor

37 Previous Clinical Trials

711,800 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Recent research and studies

clinicaltrials.govStudy

Methadone Maintenance Treatment and Smoking Cessation

2009. "Methadone Maintenance Treatment and Smoking Cessation". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00906386.

All > Smoking > Smoking Cessation

~7 spots leftby Apr 2025

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.